Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06027242

Oral Supplementation of Glutamine on Gastric Cancer Patients After Gastrectomy

Glutamine has the potentials of immunomodulation and adjustment of protein metabolism. The primary objective of this study is to evaluate the efficacy of glutamine on sarcopenia in gastric adenocarcinoma patients undergoing gastrectomy. The secondary endpoints, including the physical activity, weight loss, and nutritional profiles, will be evaluated among these patients.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Gastric Cancer Atrophy Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Gastrostomy Immunonutrition Muscular Atrophy Neoplasms Neoplasms by Site Nervous System Diseases Neurologic Manifestations Neuromuscular Manifestations Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Sarcopenia Signs and Symptoms Stomach Diseases Stomach Neoplasms

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

National Taiwan University Hospital

Taipei, 100, Taiwan

Location status: Recruiting

Location contact

Jin-Ming Wu, MD

CONTACT

[email protected]

886-223123456

About this study

This will be a double-blind, randomized, and placebo-controlled study. At least 80 evaluable patients who are scheduled for gastrectomy for gastric adenocarcinoma cancer will be randomly assigned to the control or treatment group. Each group will have at least 40 patients. The CT scan will be evaluated before surgery and on postoperative day (POD) 90. Moreover, the patient will wear the smart watch to record daily walking steps. Laboratory data will be check before gastrectomy and on POD 90.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • adult gastric cancer receiving gastrectomy

Exclusion criteria

  • Hepatic insufficiency
  • Renal insufficiency
  • can not tolerate oral or enteral feeding 7 days after gastrectomy
  • can not receive computed tomograph
  • can not waer the wearable devices

Treatment and study plan

oral glutamine

Dietary Supplement

10 g glutamine +5 g Maltodextrin for 28 days after surgery with tolerable oral intake or enteral feeding

Maltodextrin

Dietary Supplement

Maltodextrin

Primary outcomes

  1. Change of area of psoas muscle

    Time frame: 84 days after gastrectomy

    area od psoas muscle on the CT scan

Secondary outcomes

  1. Walking steps

    Time frame: 28,56, and 84 days after gastrectomy

    the average daily walking steps recorded by the wearable devices

  2. body weight

    Time frame: 84 days after gastrectomy

    body weight

  3. Change of serum albumin value

    Time frame: 84 days after gastrectomy

  4. Change in white blood cells counts

    Time frame: 84 days after gastrectomy

  5. Change in lymphocyte cells counts

    Time frame: 84 days after gastrectomy

  6. Change of serum pre-albumin value

    Time frame: 84 days after gastrectomy

Study contacts

Contact information is provided by the study sponsor or research team.

Jin-Ming Wu, MD

CONTACT

[email protected]

886+223123456

Ming-Tsan Lin, MD

CONTACT

[email protected]

Sponsors and collaborators

Lead sponsor

National Taiwan University Hospital

Other

Registry information

Important dates

Study start
2023
Primary completion
2026
Study completion
2026
First posted
Sep 7, 2023
Registry last updated
Dec 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.